|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar
|
|
2
|
Wang XN, Han X, Xu LN, Yin LH, Xu YW, Qi Y
and Peng JY: Enhancement of apoptosis of human hepatocellular
carcinoma SMMC-7721 cells through synergy of berberine and
evodiamine. Phytomedicine. 15:1062–1068. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ming ZJ, Hu Y, Qiu YH, Cao L and Zhang XG:
Synergistic effects of beta-aescin and 5-fluorouracil in human
hepatocellular carcinoma SMMC-7721 cells. Phytomedicine.
17:575–580. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Higuchi E, Oridate N, Furuta Y, Suzuki S,
Hatakeyama H, Sawa H, Sunayashiki-Kusuzaki K, Yamazaki K, Inuyama Y
and Fukuda S: Differentially expressed genes associated with
CIS-diamminedichloroplatinum (II) resistance in head and neck
cancer using differential display and CDNA microarray. Head Neck.
25:187–193. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Scotto KW and Bertino JR: Natural and
acquired resistance to chemotherapeutic agents. The Molecular Basis
of Cancer. 2nd edition. W. B. Sanders; Foster City: pp. 407–422.
2001
|
|
6
|
Johnston PG, Drake JC, Trepel J and
Allegra CJ: Immunological quantitation of thymidylate synthase
using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive
and -resistant human cancer cell lines. Cancer Res. 52:4306–4312.
1992.
|
|
7
|
Aschele C, Sobrero A, Faderan MA and
Bertino JR: Novel mechanism(s) of resistance to 5-fluorouracil in
human colon cancer (HCT-8) sublines following exposure to two
different clinically relevant dose schedules. Cancer Res.
52:1855–1864. 1992.
|
|
8
|
Copur S, Aiba K, Drake JC, Allegra CJ and
Chu E: Thymidylate synthase gene amplification in human colon
cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol.
49:1419–1426. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Berger SH, Jenh CH, Johnson LF and Berger
FG: Thymidylate synthase overproduction and gene amplification in
fluorodeoxyuridine-resistant human cells. Mol Pharmacol.
28:461–467. 1985.PubMed/NCBI
|
|
10
|
Berger SH and Berger FG: Thymidylate
synthase as a determinant of 5-fluoro-2′-deoxyuridine response in
human colonic tumor cell lines. Mol Pharmacol. 34:474–479.
1988.PubMed/NCBI
|
|
11
|
Jin S and Scotto KW: Transcriptional
regulation of the MDR1 gene by histone acetyltransferase and
deacetylase is mediated by NF-Y. Mol Cell Biol. 18:4377–4384.
1998.PubMed/NCBI
|
|
12
|
Yang AD, Fan F, Camp ER, van Buren G, Liu
W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic
oxaliplatin resistance induces epithelial-to-mesenchymal transition
in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shah AN, Summy JM, Zhang J, Park SI,
Parikh NU and Gallick GE: Development and characterization of
gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol.
14:3629–3637. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thiery JP and Chopin D: Epithelial cell
plasticity in development and tumor progression. Cancer Metastasis
Rev. 18:31–42. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Elliott BE, Hung WL, Boag AH and Tuck AB:
The role of hepatocyte growth factor (scatter factor) in
epithelial-mesenchymal transition and breast cancer. Can J Physiol
Pharmacol. 80:91–102. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chung YM, Park S, Park JK, Kim Y, Kang Y
and Yoo YD: Establishment and characterization of
5-fluorouracil-resistant gastric cancer cells. Cancer Lett.
159:95–101. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Negoro K, Yamano Y, Fushimi K, Saito K,
Nakatani K, Shiiba M, Yokoe H, Bukawa H, Uzawa K, Wada T, Tanzawa H
and Fujita S: Establishment and characterization of a
cisplatin-resistant cell line, KB-R, derived from oral carcinoma
cell line, KB. Int J Oncol. 30:1325–1332. 2007.PubMed/NCBI
|
|
19
|
Nakamura M, Nakatani K, Uzawa K, Ono K,
Uesugi H, Ogawara K, Shiiba M, Bukawa H, Yokoe H, Wada T, Fujita S
and Tanzawa H: Establishment and characterization of a
cisplatin-resistant oral squamous cell carcinoma cell line, H-1R.
Oncol Rep. 14:1281–1286. 2005.PubMed/NCBI
|
|
20
|
Nakatani K, Nakamura M, Uzawa K, Wada T,
Seki N, Tanzawa H and Fujita S: Establishment and gene analysis of
a cisplatin-resistant cell line, Sa-3R, derived from oral squamous
cell carcinoma. Oncol Rep. 13:709–714. 2005.PubMed/NCBI
|
|
21
|
Lee JH, Kim MC, Oh SY, Kwon HC, Kim SH,
Kwon KA, Lee S, Jeong JS, Choi SR and Kim HJ: Predictive value of
in vitro adeno-sine triphosphate-based chemotherapy response assay
in advanced gastric cancer patients who received oral
5-Fluorouracil after curative resection. Cancer Res Treat.
43:117–123. 2011. View Article : Google Scholar
|
|
22
|
Gamelin EC, Danquechin-Dorval EM, Dumesnil
YF, Maillart PJ, Goudier MJ, Burtin PC, Delva RG, Lortholary AH,
Gesta PH and Larra FG: Relationship between 5-fluorouracil (5-FU)
dose intensity and therapeutic response in patients with advanced
colorectal cancer receiving infusional therapy containing 5-FU.
Cancer. 77:441–451. 1996. View Article : Google Scholar
|
|
23
|
Murakami Y, Uemura K, Sudo T, Hayashidani
Y, Hashimoto Y, Ohge H and Sueda T: Impact of adjuvant gemcitabine
plus S-1 chemotherapy after surgical resection for adenocarcinoma
of the body or tail of the pancreas. J Gastrointest Surg. 13:85–92.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Uday CK, Devarayalu BVSK and Mahmood S:
Overall survival rate in breast cancer patients treated with
5-fluorouracil: a review of randomized clinical trials. Int J
Pharmaceut Biomed Res. 1:132–135. 2010.
|
|
25
|
Huang CL, Yokomise H, Kobayashi S,
Fukushima M, Hitomi S and Wada H: Intratumoral expression of
thymidylate synthase and dihydropyrimidine dehydrogenase in
non-small cell lung cancer patients treated with 5-FU-based
chemotherapy. Int J Oncol. 17:47–54. 2000.
|
|
26
|
Plasencia C, Rooney PH, Taron M,
Martinez-Balibrea E, McLeod HL and Abad A: Chromosomal imbalance
maps of human 5FU-resistant colorectal cancer cell lines:
implications in the analysis of 5FU-acquired resistance mechanisms.
Int J Oncol. 22:945–953. 2003.
|
|
27
|
Tanaka T, Bai T and Toujima S:
Establishment and characterization of monoclonal
5-fluorouracil-resistant cell lines derived from human endometrial
adenocarcinoma. Int J Oncol. 37:731–736. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wen J, Zheng B, Hu Y, Zhang X, Yang H, Luo
KJ, Li YF and Fu JH: Establishment and biological analysis of the
EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma
cell line. Oncol Rep. 22:65–71. 2009.PubMed/NCBI
|
|
29
|
Huang M and Liu G: The study of innate
drug resistance of human hepatocellular carcinoma Bel7402 cell
line. Cancer Lett. 135:97–105. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pratt S, Shepard RL, Kandasamy RA,
Johnston PA, Perry W III and Dantzig AH: The multidrug resistance
protein 5 (ABCC5) confers resistance to 5-fluorouracil and
transports its monophosphorylated metabolites. Mol Cancer Ther.
4:855–863. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nakano Y, Tanno S, Koizumi K, Nishikawa T,
Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T and Kohgo
Y: Gemcitabine chemoresistance and molecular markers associated
with gemcitabine transport and metabolism in human pancreatic
cancer cells. Br J Cancer. 96:457–463. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fukushima M, Fujioka A, Uchida J, Nakagawa
F and Takechi T: Thymidylate synthase (TS) and ribonucleotide
reductase (RNR) may be involved in acquired resistance to
5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J
Cancer. 37:1681–1687. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hinoshita E, Uchiumi T, Taguchi K,
Kinukawa N, Tsuneyoshi M, Maehara Y, Sugimachi K and Kuwano M:
Increased expression of an ATP-binding cassette superfamily
transporter, multidrug resistance protein 2, in human colorectal
carcinomas. Clin Cancer Res. 6:2401–2407. 2000.
|
|
34
|
Kruh GD and Belinsky MG: The MRP family of
drug efflux pumps. Oncogene. 22:7537–7552. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Matsuo N, Shiraha H, Fujikawa T, Takaoka
N, Ueda N, Tanaka S, Nishina S, Nakanishi Y, Uemura M, Takaki A,
Nakamura S, Kobayashi Y, Nouso K, Yagi T and Yamamoto K: Twist
expression promotes migration and invasion in hepatocellular
carcinoma. BMC Cancer. 9:240–251. 2009. View Article : Google Scholar : PubMed/NCBI
|
